Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192 SHG) stock market data APIs
¥41.95
-0.35(-0.8%)
as of February 5, 2025
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Financial Data Overview
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.
Prev. Close
42.64
Open
41.95
High
42.87
Low
41.25
52 wk Range
30.11-51.15
Market Cap
17 667 M
Shares Outstanding
418 M
Revenue
390 M
EPS
-0.5869
Beta
0.266
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dizal (Jiangsu) Pharmaceutical Co. Ltd. A data using free add-ons & libraries
Get Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Fundamental Data
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Fundamental data includes:
- Net Revenue: 390 M
- EBITDA: -924 246 720
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2023-04-28
- EPS/Forecast: NaN
Get Dizal (Jiangsu) Pharmaceutical Co. Ltd. A End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A News
New
U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib's NDA was submitted bas...
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety profile in heavily pretreated patients with EGFR-mutated NSCLC who had developed resistance to EGFR TKI...
Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting
DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacokinetic (PK) characteristics in patients with B-NHL SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- Dizal (SSE...
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug app...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
